State of New Jersey Common Pension Fund D Acquires New Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)

State of New Jersey Common Pension Fund D purchased a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 71,739 shares of the company's stock, valued at approximately $1,965,000. State of New Jersey Common Pension Fund D owned 0.08% of Myriad Genetics as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of MYGN. Hexagon Capital Partners LLC grew its stake in Myriad Genetics by 75.3% during the second quarter. Hexagon Capital Partners LLC now owns 1,143 shares of the company's stock worth $28,000 after buying an additional 491 shares during the period. Innealta Capital LLC purchased a new stake in Myriad Genetics during the 2nd quarter worth $36,000. GAMMA Investing LLC increased its holdings in Myriad Genetics by 34.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,620 shares of the company's stock valued at $44,000 after purchasing an additional 412 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in Myriad Genetics in the 2nd quarter valued at $60,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Myriad Genetics in the second quarter valued at about $82,000. Hedge funds and other institutional investors own 99.02% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on MYGN shares. Piper Sandler lowered their target price on Myriad Genetics from $30.00 to $24.00 and set a "neutral" rating for the company in a research note on Monday, November 11th. Wells Fargo & Company started coverage on shares of Myriad Genetics in a research note on Tuesday, August 27th. They set an "overweight" rating and a $35.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on shares of Myriad Genetics from $17.00 to $20.00 and gave the company an "underweight" rating in a research note on Wednesday, August 7th. Morgan Stanley dropped their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Monday. Finally, TD Cowen upped their price objective on shares of Myriad Genetics from $28.00 to $30.00 and gave the company a "hold" rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Myriad Genetics has an average rating of "Hold" and a consensus target price of $27.36.

Myriad Genetics Stock Performance

Shares of MYGN traded down $0.03 during mid-day trading on Monday, hitting $15.22. The stock had a trading volume of 1,188,663 shares, compared to its average volume of 741,917. Myriad Genetics, Inc. has a fifty-two week low of $14.91 and a fifty-two week high of $29.30. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The company has a market cap of $1.39 billion, a PE ratio of -11.71 and a beta of 1.93. The company's fifty day simple moving average is $23.19 and its two-hundred day simple moving average is $24.64.

Insider Buying and Selling

In other news, Director Colleen F. Reitan sold 46,012 shares of the company's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the completion of the transaction, the director now owns 42,533 shares in the company, valued at approximately $1,188,797.35. This represents a 51.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Paul J. Diaz sold 15,000 shares of Myriad Genetics stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $22.93, for a total transaction of $343,950.00. Following the completion of the sale, the chief executive officer now owns 962,378 shares in the company, valued at approximately $22,067,327.54. This represents a 1.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,012 shares of company stock worth $1,900,485 over the last ninety days. 2.10% of the stock is owned by insiders.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.